Immunocore names David Berman as head of R&D

UK-based T cell receptor (TCR) biotech firm Immunocore today named David Berman as its new head of research and development.

Mr Berman joined privately-held Immunocore in September 2018 to advance the company’s lead candidate, IMCgp100, towards commercialization and progress Immunocore’s growing pipeline of TCR candidates through clinical development.

Over his career, Mr Berman has worked on immuno-oncology programs at all stages of development including leadership roles in developing four approved biologics. Most recently, he was senior vice president and head of the AstraZeneca Immuno-oncology (I-O) Franchise, where he was responsible for the strategy and execution of the company’s late stage I-O program. Prior to that, he was head of the early-stage oncology program at AstraZeneca’s MedImmune unit. Mr Berman has also held senior development roles at Bristol-Myers Squibb including head of the immuno-oncology exploratory development team and global clinical lead for the first approved I-O checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma.